Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Travatan/ Timolol/Azopt

Phase 3Small molecule

SSingapore National Eye Centre

Travatan/ Timolol/Azopt is one of 2 small molecule programs targeting Primary Angle Closure Glaucoma. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Angle Closure GlaucomaActive, not recruiting

Primary Angle Closure GlaucomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Primary Angle Closure Glaucoma

#DrugCompanyPhaseTrials

Copaxone

Travatan/ Timolol/Azopt

SSingapore National Eye Centre

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Angle Closure Glaucoma1 trial

Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma

Unknown status·SSingapore National Eye Centre·Phase 3·NCT00980473·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Travatan/ Timolol/Azopt. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Travatan/ Timolol/Azopt compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Travatan/ Timolol/Azopt. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Singapore National Eye Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSingapore National Eye Centre

Related News